Provided by Tiger Trade Technology Pte. Ltd.

Enanta Pharmaceuticals

13.16
-0.0700-0.53%
Post-market: 13.160.00000.00%17:40 EDT
Volume:188.00K
Turnover:2.47M
Market Cap:381.88M
PE:-5.06
High:13.31
Open:13.19
Low:13.02
Close:13.23
52wk High:17.15
52wk Low:5.88
Shares:29.02M
Float Shares:20.83M
Volume Ratio:0.87
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6000
EPS(LYR):-3.8381
ROE:-59.00%
ROA:-11.84%
PB:3.28
PE(LYR):-3.43

Loading ...

Enanta Pharmaceuticals to speak at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives

Simply Wall St.
·
May 15

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Simply Wall St.
·
May 14

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Orchestra BioMed Holdings (OBIO)

TIPRANKS
·
May 12

Enanta Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Enanta Pharma Q2 EPS $(0.45) Beats $(0.49) Estimate, Sales $17.159M Beat $17.092M Estimate

Benzinga
·
May 12

Enanta FY26 Q2 net loss narrows to $13.1 million; revenue rises to $17.2 million

Reuters
·
May 12

BRIEF-Enanta Pharmaceuticals Q2 Revenue USD 17.159 Million Vs. IBES Estimate USD 17.1 Million

Reuters
·
May 12

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Second Quarter Ended March 31, 2026

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc - Expects Cash Runway to Fund Operations Into Fiscal 2029

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Q2 Pretax Profit USD -13.084 Million

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc - on Track to File Ind for EPS-3903 and Select Mrgprx2 Candidate in 2H 2026

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
May 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

Enanta says Phase 2 trial shows zelicapavir reduces RSV symptom duration, hospitalization

Reuters
·
May 04

Enanta announces first participant dosed in Phase 1 trial of EDP-978

TIPRANKS
·
Apr 13

Enanta doses first participant in Phase 1 trial of urticaria drug EDP-978

Reuters
·
Apr 13

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of Edp-978, an Oral, Once-Daily Kit Inhibitor, in Development for the Treatment of Urticaria

THOMSON REUTERS
·
Apr 13

Enanta Pharmaceuticals Inc - Topline Data Expected in Q4 2026

THOMSON REUTERS
·
Apr 13

Enanta to present Phase 2b zelicapavir RSV trial data at ESCMID Global 2026

Reuters
·
Apr 07